$1.12 Million in Sales Expected for Chimerix Inc. (CMRX) This Quarter

Equities research analysts predict that Chimerix Inc. (NASDAQ:CMRX) will announce $1.12 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Chimerix’s earnings, with estimates ranging from $500,000.00 to $1.73 million. Chimerix posted sales of $1.08 million during the same quarter last year, which suggests a positive year over year growth rate of 3.7%. The company is scheduled to announce its next earnings report on Tuesday, May 8th.

According to Zacks, analysts expect that Chimerix will report full-year sales of $4.25 million for the current fiscal year, with estimates ranging from $2.00 million to $6.00 million. For the next fiscal year, analysts forecast that the business will report sales of $11.25 million per share, with estimates ranging from $4.00 million to $25.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that follow Chimerix.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.07. Chimerix had a negative net margin of 1,579.53% and a negative return on equity of 29.22%. The firm had revenue of $1.84 million for the quarter, compared to analysts’ expectations of $0.83 million.

CMRX has been the topic of several recent research reports. Zacks Investment Research cut shares of Chimerix from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Chimerix in a research note on Monday, March 19th. Cowen reaffirmed a “hold” rating and set a $6.00 target price on shares of Chimerix in a research note on Thursday, March 1st. BidaskClub raised shares of Chimerix from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 15th. Finally, JPMorgan Chase cut shares of Chimerix from a “neutral” rating to an “underweight” rating in a research note on Wednesday, February 14th. Two research analysts have rated the stock with a sell rating, three have given a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. Chimerix presently has an average rating of “Hold” and an average price target of $7.06.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Nationwide Fund Advisors raised its holdings in shares of Chimerix by 70.3% during the 3rd quarter. Nationwide Fund Advisors now owns 60,567 shares of the biopharmaceutical company’s stock worth $318,000 after acquiring an additional 24,994 shares during the period. Russell Investments Group Ltd. purchased a new position in shares of Chimerix during the 3rd quarter worth $428,000. Schwab Charles Investment Management Inc. raised its holdings in shares of Chimerix by 112.3% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 200,891 shares of the biopharmaceutical company’s stock worth $1,055,000 after acquiring an additional 106,267 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Chimerix by 19.3% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,728,095 shares of the biopharmaceutical company’s stock worth $9,072,000 after acquiring an additional 279,845 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in shares of Chimerix during the 4th quarter worth $280,000. 74.39% of the stock is currently owned by institutional investors.

Chimerix stock remained flat at $$5.06 during trading on Friday. 39,069 shares of the company were exchanged, compared to its average volume of 204,891. Chimerix has a 1 year low of $4.17 and a 1 year high of $6.24. The firm has a market cap of $241.12, a PE ratio of -3.32 and a beta of 1.24.

TRADEMARK VIOLATION NOTICE: This story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://sportsperspectives.com/2018/04/16/1-12-million-in-sales-expected-for-chimerix-inc-cmrx-this-quarter.html.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Get a free copy of the Zacks research report on Chimerix (CMRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply